ESC 365 - Uncoupling ischaemic and bleeding complications: are new factor XI inhibitors too good to be true?

ESC Professional Premium Access

Uncoupling ischaemic and bleeding complications: are new factor XI inhibitors too good to be true?

Session: Adjunct pharmacology in PCI: beyond antiplatelet therapy, the next chapter

Topic: Adjunctive Pharmacotherapy

Speaker: Doctor C. Gibson (Boston, US)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor C Michael Gibson

Harvard Medical School, Boston (United States of America)

16 presentations

2 followers

4 more presentations in this session

Tackling obesity in PCI patients: biological and technical considerations

Speaker: Professor M. Roffi (Geneva, CH)

How low can you go? LDL-lowering therapy in PCI patients

Speaker: Professor K. Ray (London, GB)

Extinguishing the fire: tackling inflammation in PCI patients

Speaker: Professor D. Capodanno (Catania, IT)

Adjunct pharmacology in PCI: beyond antiplatelet therapy, the next chapter - discussion

Access the full session

Adjunct pharmacology in PCI: beyond antiplatelet therapy, the next chapter

Speakers: Doctor C. Gibson, Professor M. Roffi, Professor K. Ray, Professor D. Capodanno

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources